Clinical Trials on Hormone-Refractory Prostate Cancer
Total 12302 results
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHormone Refractory Prostate Cancer | Metastatic Prostate CarcinomaChina
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupAstellas Pharma Inc; Apices Soluciones S.L.CompletedHormone-refractory Prostate CancerSpain
-
Peking UniversityWithdrawnHormone Refractory Prostate CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownHormone Refractory Prostate CancerChina
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
British Columbia Cancer AgencyCompletedHormone Refractory Prostate CancerCanada
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
-
Poniard PharmaceuticalsUnknownHormone Refractory Prostate CancerRussian Federation
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate CancerUnited States
-
CelgeneCompletedHormone Refractory Prostate CancerUnited States
-
Queen's Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHormone Refractory Prostate CancerUnited States
-
Spanish Oncology Genito-Urinary GroupCompleted
-
Daniel George, MDNovartis PharmaceuticalsCompletedHormone Refractory Prostate CancerUnited States
-
DendreonCompletedHormone-Refractory Prostate Cancer
-
Medical University of ViennaUnknownHormone Refractory Prostate CancerAustria
-
Sheba Medical CenterUnknownHormone Refractory Prostate CancerIsrael
-
Korean Cancer Study GroupCompletedHormone Refractory Prostate CancerKorea, Republic of
-
Zealand University HospitalUniversity Hospital Schleswig-HolsteinUnknownHormone-refractory Prostate CancerDenmark, Germany
-
AgennixCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
-
Veeda OncologyBayerTerminatedHormone Refractory Prostate CancerUnited States
-
Zhengzhou UniversityThe First Affiliated Hospital of Zhengzhou University; Xinyang Central Hospital and other collaboratorsUnknown
-
CytoVac A/SCompletedHormone-refractory Prostate CancerDenmark
-
University of FloridaCureVacTerminated
-
National University Hospital, SingaporeCompletedHormone-Refractory Prostate CancerSingapore
-
CytRxCompletedHormone Refractory Prostate CancerUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States, Russian Federation
-
Merrion Pharmaceuticals, LLCCompletedHormone-Refractory Prostate CancerUnited States, Estonia, Latvia
-
David M LubaroffUnited States Department of DefenseCompletedHormone Refractory Prostate CancerUnited States
-
Duke UniversityUnited States Department of DefenseCompletedMetastatic Hormone Refractory Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone Refractory Prostate CancerUnited States, Canada
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate Cancer DiseaseUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
Nerviano Medical SciencesCompletedMetastatic Hormone Refractory Prostate CancerItaly
-
Achieve Life SciencesTeva Pharmaceuticals USATerminatedHormone Refractory Prostate Cancer | Castrate-Resistant Prostate CancerFrance, United States, Spain, United Kingdom, Canada
-
CureVacCompletedHormonal Refractory Prostate CancerGermany, Italy
-
National Health Research Institutes, TaiwanCompletedHormone-refractory Prostate CancerTaiwan
-
Oxford BioMedicaMedSource LLCTerminatedHormone Refractory Prostate CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedHormone-refractory Prostate CancerUnited States
-
Astellas Pharma IncAstellas Pharma US, Inc.TerminatedProstatic Neoplasms | Hormone-Refractory Prostate CancerUnited States, Ireland, Australia, France, United Kingdom, Belgium, Germany, Netherlands, Poland, Spain
-
Alberta Health servicesAmersham Health; The Prostate Cancer Research Foundation of CanadaCompletedBone Metastases | Hormone Refractory Prostate CancerCanada
-
Sandy SrinivasWyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaboratorsTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Stanford UniversityTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Alberta Health servicesPfizerUnknown
-
Amunix, a Sanofi CompanyRecruitingHormone-refractory Prostate CancerAustralia, Spain, United Kingdom
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust and other collaboratorsRecruitingHormone Refractory Prostate CancerUnited Kingdom